People with diabetes and motor impairments of the hands are often unable to push the insulin pen through properly. As a result, insulin therapy cannot be administered optimally. However, successful insulin therapy depends on the correct injection technique. If this is not the case, the efficiency of the therapy is jeopardized. Approximately half of all diabetes patients are affected by motor impairments of the hands.1
With the Liprolog® 200 units/ml KwikPen®*, BERLIN-CHEMIE has a modern ready-to-use pen in its product portfolio that is easy to handle for people with poor injection technique or limited motor skills thanks to its one-button operation and the low amount of force required for injecting.2 This message of the significant ease of use of the product had to be conveyed sustainably and concisely to the practices via the sales force.
"It was important to us to highlight the advantages of the Liprolog KwikPen with an extraordinary as well as attention-grabbing campaign," Patrizia Profeta, Product Manager at BERLIN-CHEMIE, explains the campaign. "Schmittgall HEALTH has succeeded in this in a convincing way with the "YES WE PEN" campaign."
The campaign will be played in diabetes trade media with a wide reach and will be accompanied by comprehensive measures for customer field service communication.
*Already for adult patients requiring > 20 units of short-acting insulin per day.
- Gentile S et al. Expert Opin Drug Saf 2018; 17(5): 445-450, Open-label, randomized, comparative, monocentric cross-over study over 2x 12 weeks (n=126) comparing insulin lispro 100 E/ml KwikPen with insulin lispro 200 E/ml KwikPen with respect to HbA1c levels, hypoglycemias, and insulin dose; HbA1c reduction of up to 1.0%, significant reduction in the number of hypoglycemias, and significant reduction in meal insulin after switching from insulin lispro 100 E/ml KwikPen to insulin lispro 200 E/ml KwikPen.
- Rees TM et al. J Diabetes Sci Technol 2015; 9(2): 316-319. Significantly lower compressive force (25% to 53% reduction at 30 E dose and 6 or 9 E/s; 25% to 52% reduction at 60 E dose and 6 or 9 E/s) required to push through insulin lispro 200 E/ml KwikPen compared with insulin lispro 100 E/ml KwikPen. Testing was performed using the Zwick Linear Test System with injection speed 9 or 6 E/s, 5mm thin-wall or extra-thin-wall needles and for 30 or 60 units/injection.